EYE1090

EYE1090 inhibits purified VEGFR2 kinase with an IC₅₀ of 13 nM in the dark, and illumination enhances this potency to an IC₅₀ of 3 nM^[1].
EYE1090 (0.1-100 μM; 24 h) reduces NIH/3T3 fibroblast viability in a dose-dependent manner^[1].
EYE1090 (50 min pre-incubation; 10 min light exposure; 4 h VEGF stimulation) inhibits VEGF-induced VEGFR2 signaling in VEGFR2/NFAT Reporter-HEK293 cells with an IC₅₀ of 19.06 nM in the dark under cold white LED conditions, 21.75 nM under red LED conditions, and 33.37 nM under green LED conditions; illumination with cold white or green LED significantly enhances potency, while red LED has no effect^[1].
EYE1090 (1-100 nM; 1 h pre-incubation; 10 min light exposure; 10 min VEGF stimulation) does not significantly inhibit VEGF-induced VEGFR2 phosphorylation at Y⁹⁵¹ or Y¹¹⁷⁵ in VEGFR2/NFAT Reporter-HEK293 cells in the dark, but light exposure triggers potent inhibition of phosphorylation at these sites^[1].
EYE1090 (0.1 nM-10 μM; 10 min pre-incubation; 10 min light exposure; 12 h incubation) inhibits HRMEC tubulogenesis with an IC₅₀ of 410 nM in the dark, and light exposure enhances this potency to an IC₅₀ of 133 nM, eliminating the potency gap with sunitinib^[1].
EYE1090 (0.001-10 μM; 10 min pre-incubation; 10 min light exposure; 6 h migration incubation) inhibits HRMEC migration with an IC₅₀ of 1012 nM in the dark, and light exposure enhances this potency to an IC₅₀ of 474 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.